

# Fabrizio Stocchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5154298/publications.pdf>

Version: 2024-02-01

310  
papers

19,842  
citations

13087

68  
h-index

13365

130  
g-index

333  
all docs

333  
docs citations

333  
times ranked

12178  
citing authors

#	ARTICLE	IF	CITATIONS
1	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1641-1649.	2.2	1,171
2	International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. <i>Movement Disorders</i> , 2006, 21, 916-923.	2.2	865
3	The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. <i>Movement Disorders</i> , 2007, 22, 1901-1911.	2.2	838
4	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278.	13.9	830
5	Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. <i>Lancet, The</i> , 2005, 365, 947-954.	6.3	601
6	Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. <i>Lancet Neurology, The</i> , 2006, 5, 677-687.	4.9	461
7	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; Study using nonmotor symptoms questionnaire in 545 patients. <i>Movement Disorders</i> , 2007, 22, 1623-1629.	2.2	461
8	A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. <i>Lancet, The</i> , 2005, 365, 412-415.	6.3	449
9	Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1064-1071.	2.2	374
10	A frequent gene mutation associated with autosomal dominant Parkinson's disease. <i>Lancet, The</i> , 2005, 365, 412-415.	6.3	373
11	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. <i>Movement Disorders</i> , 2010, 25, 704-709.	2.2	342
12	Validation of the freezing of gait questionnaire in patients with Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 655-661.	2.2	332
13	Levodopa in the treatment of Parkinson's disease: Current controversies. <i>Movement Disorders</i> , 2004, 19, 997-1005.	2.2	331
14	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-EPD study. <i>Annals of Neurology</i> , 2010, 68, 18-27.	2.8	330
15	Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes. <i>Neurology</i> , 2005, 65, 87-95.	1.5	323
16	ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. <i>Neurology</i> , 2007, 68, 1557-1562.	1.5	312
17	Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease. <i>Neurology</i> , 2007, 68, 1108-1115.	1.5	288
18	Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. <i>Movement Disorders</i> , 1998, 13, 39-45.	2.2	262

#	ARTICLE	IF	CITATIONS
19	Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. <i>Movement Disorders</i> , 2014, 29, 229-237.	2.2	239
20	Identification of motor and nonmotor wearing-off in Parkinson's disease: Comparison of a patient questionnaire versus a clinician assessment. <i>Movement Disorders</i> , 2005, 20, 726-733.	2.2	219
21	Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease. <i>Archives of Neurology</i> , 2005, 62, 905-10.	4.9	206
22	Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1273-1280.	2.2	200
23	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , The, 2011, 10, 415-423.	4.9	192
24	The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. <i>Journal of Medical Genetics</i> , 2005, 42, e65-e65.	1.5	178
25	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008, 23, 2194-2201.	2.2	162
26	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , 2006, 14, 322-331.	1.4	152
27	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. <i>Neurobiology of Aging</i> , 2020, 85, 58-73.	1.5	150
28	Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 62, 507-511.	0.9	149
29	Continuous dopamine-receptor stimulation in advanced Parkinson's disease. <i>Trends in Neurosciences</i> , 2000, 23, S109-S115.	4.2	148
30	Adherence to antiparkinson medication in a multicenter European study. <i>Movement Disorders</i> , 2009, 24, 826-832.	2.2	146
31	Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. <i>Brain</i> , 2002, 125, 2058-2066.	3.7	145
32	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010, 257, 5-14.	1.8	140
33	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. <i>Movement Disorders</i> , 1998, 13, 46-51.	2.2	135
34	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013, 28, 1838-1846.	2.2	122
35	Early DEtection of wEaring off in Parkinson disease: The DEEP study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 204-211.	1.1	121
36	Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 382-392.	2.7	117

#	ARTICLE	IF	CITATIONS
37	The spectrum of "off" in Parkinson's disease: What have we learned over 40 years?. <i>Parkinsonism and Related Disorders</i> , 2018, 51, 9-16.	1.1	115
38	Sleep disorders in Parkinson's disease. <i>Journal of Neurology</i> , 1998, 245, S15-S18.	1.8	114
39	A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. <i>Neurology</i> , 1999, 53, 1415-1415.	1.5	112
40	A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. <i>Movement Disorders</i> , 2012, 27, 106-112.	2.2	106
41	Efficacy and Tolerability of Paroxetine for the Long-Term Treatment of Generalized Anxiety Disorder. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 250-258.	1.1	103
42	Improvement of motor function in early Parkinson disease by safinamide. <i>Neurology</i> , 2004, 63, 746-748.	1.5	101
43	Wearing scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2011, 26, 2169-2175.	2.2	101
44	Anorectal function in multiple system atrophy and Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 71-76.	2.2	99
45	Treatment of levodopa-induced motor complications. <i>Movement Disorders</i> , 2008, 23, S599-S612.	2.2	98
46	Prevalence of fatigue in Parkinson disease and its clinical correlates. <i>Neurology</i> , 2014, 83, 215-220.	1.5	98
47	Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. <i>Current Medical Research and Opinion</i> , 2008, 24, 2883-2895.	0.9	97
48	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. <i>PLoS ONE</i> , 2013, 8, e57221.	1.1	95
49	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 287-291.	1.1	93
50	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019, 142, 3592-3604.	3.7	90
51	Direct genetic evidence for involvement of tau in progressive supranuclear palsy. <i>Neurology</i> , 1998, 51, 982-985.	1.5	89
52	When Do Levodopa Motor Fluctuations First Appear in Parkinson's Disease?. <i>European Neurology</i> , 2010, 63, 257-266.	0.6	89
53	Levodopa: A new look at an old friend. <i>Movement Disorders</i> , 2018, 33, 859-866.	2.2	89
54	Neuroprotection in Parkinson's disease: Clinical trials. <i>Annals of Neurology</i> , 2003, 53, S87-S99.	2.8	88

#	ARTICLE	IF	CITATIONS
55	Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. <i>Neurological Sciences</i> , 2001, 22, 93-94.	0.9	86
56	The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1399-1407.	0.9	85
57	Constipation in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 134, 811-826.	0.9	82
58	Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 644-649.	1.1	81
59	Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 271-280.	1.7	80
60	Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 1491.	4.5	80
61	End-of-dose Wearing Off in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2006, 29, 312-321.	0.2	78
62	A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1356-1365.	2.2	78
63	Smoking habits in multiple system atrophy and progressive supranuclear palsy. <i>Neurology</i> , 2000, 54, 114-114.	1.5	77
64	Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: An international multicenter study. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1231-1235.	1.1	76
65	Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2017, 55, 143-158.	1.5	76
66	Continuous dopaminergic stimulation in early and advanced Parkinson's disease. <i>Neurology</i> , 2004, 62, S56-63.	1.5	76
67	A pharmacological study of dopaminergic receptors in planaria. <i>Neuropharmacology</i> , 1989, 28, 1377-1382.	2.0	73
68	Strategies for Treating Patients with Advanced Parkinson's Disease with Disastrous Fluctuations and Dyskinesias. <i>Clinical Neuropharmacology</i> , 1997, 20, 95-115.	0.2	73
69	Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. <i>Movement Disorders</i> , 2018, 33, 1528-1539.	2.2	73
70	COMT inhibitors in Parkinson's disease. <i>Neurology</i> , 2004, 62, S72-81.	1.5	70
71	PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1259-1265.	2.2	69
72	A pharmacological study of cocaine activity in planaria. <i>Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology</i> , 1996, 115, 41-45.	0.5	65

#	ARTICLE	IF	CITATIONS
73	Caseâ€“control study of multiple system atrophy. <i>Movement Disorders</i> , 2005, 20, 158-163.	2.2	65
74	Symptom relief in Parkinson disease by safinamide. <i>Neurology</i> , 2006, 67, S24-9.	1.5	65
75	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. <i>Alzheimer's and Dementia</i> , 2021, 17, 1528-1553.	0.4	64
76	Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. <i>Movement Disorders</i> , 2010, 25, 896-905.	2.2	63
77	Continuous dopaminergic stimulation and novel formulations of dopamine agonists. <i>Journal of Neurology</i> , 2011, 258, 316-322.	1.8	62
78	Comparison of IPX066 with carbidopaâ€“levodopa plus entacapone in advanced PD patients. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1335-1340.	1.1	62
79	Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2018, 65, 18-40.	1.5	61
80	Novel parkin mutations detected in patients with early-onset Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 424-431.	2.2	60
81	The â€œGender Factorâ€“in Wearing-Off among Patients with Parkinsonâ€™s Disease: A Post Hoc Analysis of DEEP Study. <i>Scientific World Journal</i> , The, 2015, 2015, 1-10.	0.8	59
82	Randomized trial of pramipexole, given as monotherapy, in patients with early Parkinson disease. <i>Neurology</i> , 2017, 88, 2198-2206.	1.5	58
83	Move for Change Part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinsonâ€™s disease. <i>European Journal of Neurology</i> , 2012, 19, 402-410.	1.7	56
84	Low Dose of Clozapine in the Treatment of Dopaminergic Psychosis in Parkinsonâ€™s Disease. <i>Clinical Neuropharmacology</i> , 1997, 20, 204-209.	0.2	55
85	Modification of respiratory function parameters in patients with severe Parkinson's disease. <i>Neurological Sciences</i> , 2002, 23, s69-s70.	0.9	55
86	Bilateral Implantation of Centromedian-Parafascicularis Complex and GPi: A New Combination of Unconventional Targets for Deep Brain Stimulation in Severe Parkinson Disease. <i>Neuromodulation</i> , 2006, 9, 221-228.	0.4	55
87	Robot-assisted walking training for individuals with Parkinsonâ€™s disease: a pilot randomized controlled trial. <i>BMC Neurology</i> , 2013, 13, 50.	0.8	55
88	Mavoglurant in Parkinson's patients with<sc> </sc>-Dopa-induced dyskinesias: Two randomized phase 2 studies. <i>Movement Disorders</i> , 2016, 31, 1054-1058.	2.2	55
89	The Bereitschaftspotential preceding simple foot movement and initiation of gait in Parkinson's disease. <i>Neurology</i> , 1993, 43, 1784-1784.	1.5	54
90	Corneal and blink reflexes in Parkinson's disease with ?on-off? fluctuations. <i>Movement Disorders</i> , 1987, 2, 227-235.	2.2	53

#	ARTICLE	IF	CITATIONS
91	The Long-Duration Action of Levodopa May Be Due to a Postsynaptic Effect. <i>Clinical Neuropharmacology</i> , 1997, 20, 394-401.	0.2	53
92	A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. <i>Journal of Neural Transmission</i> , 2002, 109, 489-501.	1.4	53
93	CONTINUOUS APOMORPHINE INFUSION (CAI) AND NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE: A FOLLOW-UP OF TWO YEARS. <i>Archives of Gerontology and Geriatrics</i> , 2004, 38, 291-296.	1.4	53
94	Epidemiology of multiple system atrophy. <i>Neurological Sciences</i> , 2001, 22, 97-99.	0.9	52
95	Classification of Healthy Subjects and Alzheimer's Disease Patients with Dementia from Cortical Sources of Resting State EEG Rhythms: A Study Using Artificial Neural Networks. <i>Frontiers in Neuroscience</i> , 2016, 10, 604.	1.4	51
96	Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 247-268.	1.2	50
97	Obstacles to the Development of a Neuroprotective Therapy for Parkinson's Disease. <i>Movement Disorders</i> , 2013, 28, 3-7.	2.2	48
98	Analysis of repetitive and nonrepetitive sequential arm movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 1994, 9, 311-314.	2.2	46
99	Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S233-S236.	1.1	46
100	Comparison Between a Fast and a Slow Release Preparation of Levodopa and a Combination of the Two. <i>Clinical Neuropharmacology</i> , 1994, 17, 38-44.	0.2	45
101	Long-term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1489-1496.	2.2	45
102	Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases: An EEG Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 339-358.	1.2	45
103	Functional cortical source connectivity of resting state electroencephalographic alpha rhythms shows similar abnormalities in patients with mild cognitive impairment due to Alzheimer's and Parkinson's diseases. <i>Clinical Neurophysiology</i> , 2018, 129, 766-782.	0.7	45
104	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 920-929.	0.8	45
105	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic" neurology. <i>European Journal of Neurology</i> , 2021, 28, 1752-1758.	1.7	45
106	Timed Up and Go evaluation with wearable devices: Validation in Parkinson's disease. <i>Journal of Bodywork and Movement Therapies</i> , 2018, 22, 390-395.	0.5	45
107	Repeated Levodopa Infusions in Fluctuating Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1986, 9, 165-181.	0.2	44
108	Correlation between facial involuntary movements and abnormalities of blink and corneal reflexes in Huntington's chorea. <i>Movement Disorders</i> , 1988, 3, 281-289.	2.2	42

#	ARTICLE	IF	CITATIONS
109	Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. <i>Neurological Sciences</i> , 2002, 23, s59-s60.	0.9	40
110	Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. <i>Neurological Sciences</i> , 2003, 24, 174-175.	0.9	39
111	Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor. <i>Neurological Sciences</i> , 2003, 24, 217-218.	0.9	39
112	Prevention and treatment of motor fluctuations. <i>Parkinsonism and Related Disorders</i> , 2003, 9, 73-81.	1.1	37
113	Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. <i>European Journal of Neurology</i> , 2011, 18, 1373-1378.	1.7	37
114	Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease. <i>European Journal of Neurology</i> , 2014, 21, 357-360.	1.7	37
115	Advances in dopamine receptor agonists for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1889-1902.	0.9	37
116	Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. <i>Italian Journal of Neurological Sciences</i> , 1993, 14, 361-367.	0.1	36
117	Long-duration effect and the postsynaptic compartment: Study using a dopamine agonist with a short half-life. <i>Movement Disorders</i> , 2001, 16, 301-305.	2.2	36
118	The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S9-S15.	1.1	36
119	Rasagiline for the treatment of Parkinson's disease: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2231-2241.	0.9	36
120	Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. <i>Drug Design, Development and Therapy</i> , 2016, 10, 609.	2.0	36
121	Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 576-585.	0.8	36
122	Dual dopamine agonist treatment in Parkinson's disease. <i>Journal of Neurology</i> , 2003, 250, 822-826.	1.8	35
123	Robot-assisted gait training versus treadmill training in patients with Parkinson's disease: a kinematic evaluation with gait profile score. <i>Functional Neurology</i> , 2016, 31, 163-70.	1.3	35
124	The Parkinsonian Gait Spatiotemporal Parameters Quantified by a Single Inertial Sensor before and after Automated Mechanical Peripheral Stimulation Treatment. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	0.6	33
125	Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. <i>Neurobiology of Aging</i> , 2019, 77, 112-127.	1.5	33
126	Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 177-186.	1.5	33



#	ARTICLE	IF	CITATIONS
127	Clinical Efficacy of a Single Afternoon Dose of Effervescent Levodopa-Carbidopa Preparation (CHF) Tj ETQq1 1 0.784314 rgBT <sub>3</sub> /Overlook	0.2	32
128	Factors influencing psychological well-being in patients with Parkinson's disease. PLoS ONE, 2017, 12, e0189682.	1.1	32
129	A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases. Current Pharmaceutical Design, 2014, 20, 5945-5956.	0.9	32
130	The Bereitschaftspotential preceding stepping in patients with isolated gait ignition failure. Movement Disorders, 1995, 10, 18-21.	2.2	31
131	Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?. Expert Opinion on Pharmacotherapy, 2018, 19, 1821-1828.	0.9	31
132	HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson's disease. Movement Disorders, 2003, 18, 337-340.	2.2	30
133	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. Neurobiology of Aging, 2020, 90, 43-59.	1.5	30
134	Stacked autoencoders as new models for an accurate Alzheimer's disease classification support using resting-state EEG and MRI measurements. Clinical Neurophysiology, 2021, 132, 232-245.	0.7	30
135	Epidemiology of progressive supranuclear palsy. Neurological Sciences, 2001, 22, 101-103.	0.9	29
136	The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, S68-S71.	1.1	29
137	Non motor symptoms in progressive supranuclear palsy: prevalence and severity. Npj Parkinson's Disease, 2017, 3, 35.	2.5	29
138	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Movement Disorders, 2016, 31, 1049-1054.	2.2	28
139	Optimising levodopa therapy for the management of Parkinson's disease. Journal of Neurology, 2005, 252, iv43-iv48.	1.8	27
140	The Clinical Efficacy of Single Morning Doses of Levodopa Methyl Ester. Clinical Neuropharmacology, 1992, 15, 501-504.	0.2	26
141	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. Neuroscience Letters, 1999, 274, 61-65.	1.0	26
142	End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. Journal of Neurology, 2006, 253, 1633-1639.	1.8	26
143	Move for Change Part II: a European survey evaluating the impact of the EPDA Charter for people with Parkinson's disease. European Journal of Neurology, 2013, 20, 461-472.	1.7	26
144	The Vatican Meeting on Neuroprotection for Parkinson's Disease. Movement Disorders, 2013, 28, 1-2.	2.2	26

#	ARTICLE	IF	CITATIONS
145	Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms. <i>Neurobiology of Aging</i> , 2019, 73, 9-20.	1.5	26
146	Pathological gambling in Parkinson's disease. <i>Lancet Neurology</i> , The, 2005, 4, 590-592.	4.9	25
147	Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. <i>Neurological Sciences</i> , 2012, 33, 1319-1327.	0.9	25
148	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2269-2280.	0.9	25
149	Move for Change Part III: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's Disease. <i>European Journal of Neurology</i> , 2015, 22, 133-141.	1.7	25
150	Correlation Between the Overactive Bladder Questionnaire (OAB-q) and Urodynamic Data of Parkinson Disease Patients Affected by Neurogenic Detrusor Overactivity During Antimuscarinic Treatment. <i>Clinical Neuropharmacology</i> , 2006, 29, 220-229.	0.2	24
151	mGlu3 metabotropic glutamate receptors modulate the differentiation of SVZ-derived neural stem cells towards the astrocytic lineage. <i>Glia</i> , 2010, 58, 813-822.	2.5	24
152	Are All Dopamine Agonists Essentially the Same?. <i>Drugs</i> , 2019, 79, 693-703.	4.9	24
153	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. <i>Neurobiology of Aging</i> , 2020, 91, 88-111.	1.5	24
154	Acute Modulation of Brain Connectivity in Parkinson Disease after Automatic Mechanical Peripheral Stimulation: A Pilot Study. <i>PLoS ONE</i> , 2015, 10, e0137977.	1.1	24
155	SIDE-EFFECTS OF SUBCUTANEOUS APOMORPHINE IN PARKINSON'S DISEASE. <i>Lancet</i> , The, 1989, 333, 566.	6.3	23
156	Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. <i>Journal of Neurology</i> , 2013, 260, 1731-1742.	1.8	23
157	How to optimize the treatment of early stage Parkinson's disease. <i>Translational Neurodegeneration</i> , 2015, 4, 4.	3.6	23
158	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinson's Disease</i> , 2021, 7, 48.	2.5	23
159	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. <i>Journal of Neurology</i> , 2022, 269, 1335-1352.	1.8	23
160	Consensus on the treatment of dysphagia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021, 430, 120008.	0.3	23
161	Motor Fluctuations in Levodopa Treatment: Clinical Pharmacology. <i>European Neurology</i> , 1996, 36, 38-42.	0.6	22
162	Use of apomorphine in Parkinson's disease. <i>Neurological Sciences</i> , 2008, 29, 383-386.	0.9	22

#	ARTICLE	IF	CITATIONS
163	GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 703-705.	1.1	22
164	Therapy for Parkinson's Disease: What is in the Pipeline?. <i>Neurotherapeutics</i> , 2014, 11, 24-33.	2.1	22
165	Transient atrial fibrillation after subcutaneous apomorphine bolus. <i>Movement Disorders</i> , 1996, 11, 584-585.	2.2	21
166	Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. <i>Journal of Neurology</i> , 1996, 243, 377-380.	1.8	21
167	Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1881-1887.	2.2	21
168	Apomorphine and lisuride infusion. A comparative chronic study. <i>Advances in Neurology</i> , 1993, 60, 653-5.	0.8	21
169	Peripheral blood mononuclear cells from mild cognitive impairment patients show deregulation of Bax and Sod1 mRNAs. <i>Neuroscience Letters</i> , 2009, 453, 36-40.	1.0	20
170	Temporal stability of the Unified Dyskinesia Rating Scale. <i>Movement Disorders</i> , 2011, 26, 2556-2559.	2.2	20
171	Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report. <i>Frontiers in Human Neuroscience</i> , 2014, 8, 207.	1.0	20
172	Validity of the wall goniometer as a screening tool to detect postural abnormalities in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 159-165.	1.1	20
173	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 <sc>Year</sc> Data from the <sc>OpenLabel BeyoND</sc> Study. <i>Movement Disorders</i> , 2021, 36, 2687-2692.	2.2	20
174	Single-Dose Studies of a Slow-Release Preparation of Levodopa and Benserazide (Madopar HBS) in Parkinson's Disease. <i>European Neurology</i> , 1987, 27, 54-58.	0.6	19
175	Simultaneous measurement of l-DOPA, its metabolites and carbidopa in plasma of Parkinsonian patients by improved sample pretreatment and high-performance liquid chromatographic determination. <i>Journal of Chromatography A</i> , 1990, 511, 167-176.	1.8	19
176	The Clinical Efficacy of Oral Levodopa Methyl Ester Solution in Reversing Afternoon "Off" Periods in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1991, 14, 241-244.	0.2	19
177	Intravenous boluses and continuous infusions of l-DOPA methyl ester in fluctuating patients with Parkinson's disease. <i>Movement Disorders</i> , 1992, 7, 249-256.	2.2	19
178	The relevance of dopaminergic level in nocturnal disability in Parkinson's disease: implications of continuous dopaminergic stimulation at night to treat the symptoms. <i>Journal of Neural Transmission</i> , 2014, 121, 79-83.	1.4	19
179	Are there consistent abnormalities in event-related EEG oscillations in patients with Alzheimer's disease compared to other diseases belonging to dementia?. <i>Psychophysiology</i> , 2022, 59, e13934.	1.2	19
180	Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. <i>Journal of Neural Transmission</i> , 2004, 111, 173-180.	1.4	18

#	ARTICLE	IF	CITATIONS
181	Metabotropic glutamate receptors regulate differentiation of embryonic stem cells into GABAergic neurons. <i>Cell Death and Differentiation</i> , 2008, 15, 700-707.	5.0	18
182	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012, 33, 585-593.	0.9	18
183	Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. <i>Neurological Sciences</i> , 2012, 33, 689-694.	0.9	18
184	Long-term effects of automated mechanical peripheral stimulation on gait patterns of patients with Parkinson's disease. <i>International Journal of Rehabilitation Research</i> , 2015, 38, 238-245.	0.7	18
185	The Parkinson's Disease Composite Scale: results of the first validation study. <i>European Journal of Neurology</i> , 2018, 25, 503-511.	1.7	18
186	Early morning OFF and levodopa dose failures in patients with Parkinson's disease attending a routine clinical appointment using Timeâ€œ ON Questionnaire. <i>European Journal of Neurology</i> , 2019, 26, 821-826.	1.7	18
187	Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1663-1675.	1.5	18
188	The Lee Silverman Voice Treatment (LSVTâ€œ) speech therapy in progressive supranuclear palsy. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2015, 51, 569-74.	1.1	18
189	JEJUNAL DELIVERY OF LEVODOPA METHYL ESTER. <i>Lancet</i> , The, 1989, 334, 45-46.	6.3	17
190	Ambulatory blood pressure monitoring and cardiovascular function tests in multiple system atrophy. <i>Fundamental and Clinical Pharmacology</i> , 1995, 9, 187-196.	1.0	17
191	Determination of apomorphine in human plasma by alumina extraction and high-performance liquid chromatography with electrochemical detection. <i>Forensic Science International</i> , 1997, 89, 81-91.	1.3	17
192	The Concept of Continuous Dopaminergic Stimulation: What We Should Consider when Starting Parkinson's Disease Treatment. <i>Neurodegenerative Diseases</i> , 2010, 7, 213-215.	0.8	17
193	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 448-454.	1.8	16
194	On-Demand Therapy for OFF Episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2244-2253.	2.2	16
195	Comparison between L-Dopa and lisuride intravenous infusions: A clinical study. <i>Movement Disorders</i> , 1988, 3, 313-319.	2.2	15
196	Improved high-performance liquid chromatographic analysis with double detection system for L-DOPA, its metabolites and carbidopa in plasma of Parkinsonian patients under L-DOPA therapy. <i>Journal of Chromatography A</i> , 1988, 459, 341-349.	1.8	15
197	The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 219-222.	1.1	15
198	Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1189-1195.	1.5	15

#	ARTICLE	IF	CITATIONS
199	Does the Degree of Trunk Bending Predict Patient Disability, Motor Impairment, Falls, and Back Pain in Parkinson's Disease?. <i>Frontiers in Neurology</i> , 2020, 11, 207.	1.1	15
200	Variation in the Dopaminergic Response During the Day in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 116-118.	0.2	14
201	Factors Associated With Motor Fluctuations and Dyskinesia in Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2010, 33, 198-203.	0.2	14
202	Clinical Experiences With Levodopa Methylester (Melevodopa) in Patients With Parkinson Disease Experiencing Motor Fluctuations. <i>Clinical Neuropharmacology</i> , 2010, 33, 61-66.	0.2	14
203	Mutations in TMEM230 are not a common cause of Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 302-304.	2.2	14
204	Resting-state electroencephalographic delta rhythms may reflect global cortical arousal in healthy old seniors and patients with Alzheimer's disease dementia. <i>International Journal of Psychophysiology</i> , 2020, 158, 259-270.	0.5	14
205	Abnormalities of Cortical Sources of Resting State Alpha Electroencephalographic Rhythms are Related to Education Attainment in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. <i>Cerebral Cortex</i> , 2021, 31, 2220-2237.	1.6	14
206	Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study. <i>European Journal of Neurology</i> , 2021, 28, 349-354.	1.7	14
207	The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo. <i>Functional Neurology</i> , 1994, 9, 259-64.	1.3	14
208	LISURIDE INFUSION PUMP FOR PARKINSON'S DISEASE. <i>Lancet, The</i> , 1986, 328, 348-349.	6.3	13
209	Botulinum A toxin injection in patients with blepharospasm, torticollis and hemifacial spasm. <i>Italian Journal of Neurological Sciences</i> , 1990, 11, 589-593.	0.1	13
210	Apomorphine Infusion and the Long-Duration Response to Levodopa in Advanced Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 2003, 26, 151-155.	0.2	13
211	Dopamine receptor agonists in the treatment of advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S54-S57.	1.1	13
212	The Possible Clinical Predictors of Fatigue in Parkinson's Disease: A Study of 135 Patients as Part of International Nonmotor Scale Validation Project. <i>Parkinson's Disease</i> , 2011, 2011, 1-7.	0.6	13
213	Extended release levodopa at bedtime as a treatment for nocturia in Parkinson's disease: An open label study. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116625.	0.3	13
214	Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. <i>International Journal of Clinical Practice</i> , 2006, 60, 215-221.	0.8	12
215	Cardiovascular Effects of Lisuride Continuous Intravenous Infusion in Fluctuating Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1989, 12, 331-338.	0.2	11
216	Transient cardiac arrest during continuous intravenous infusion of apomorphine. <i>Lancet, The</i> , 1990, 336, 1321.	6.3	11

#	ARTICLE	IF	CITATIONS
217	Dopamine Agonists in Parkinson's Disease. <i>CNS Drugs</i> , 1998, 10, 159-170.	2.7	11
218	L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	11
219	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 649-659.	1.4	11
220	Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study. <i>Movement Disorders</i> , 2019, 34, 425-429.	2.2	11
221	Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. <i>Clinical Neurophysiology</i> , 2020, 131, 2716-2731.	0.7	11
222	The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 2507-2517.	2.0	11
223	The relation between Parkinson's disease and ageing. Comparison of the gait patterns of young Parkinson's disease subjects with healthy elderly subjects. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2013, 49, 161-7.	1.1	11
224	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases. <i>Neurobiology of Aging</i> , 2022, 115, 88-108.	1.5	11
225	Clinical Efficacy of Single Morning Doses of Different Levodopa Formulations. <i>Clinical Neuropharmacology</i> , 1994, 17, S16-S20.	0.2	10
226	Drug safety evaluation of ropinirole prolonged release. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 383-389.	1.0	10
227	Analyzing gait variability and dual-task interference in patients with Parkinson's disease and freezing by means of the word-color Stroop test. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 1137-1142.	1.4	10
228	Effect of family history, occupation and diet on the risk of Parkinson disease: A case-control study. <i>PLoS ONE</i> , 2020, 15, e0243612.	1.1	10
229	Utility of tolcapone in fluctuating Parkinson's disease. <i>Clinical Interventions in Aging</i> , 2006, 1, 317-325.	1.3	9
230	Multicenter trial of L-Deprenylin Parkinson disease. <i>Italian Journal of Neurological Sciences</i> , 1986, 7, 133-137.	0.1	8
231	Effects of Terguride in Patients with Huntington's Disease. <i>Clinical Neuropharmacology</i> , 1989, 12, 435-439.	0.2	8
232	Antagonist Effect of Terguride in Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1991, 14, 450-456.	0.2	8
233	TRH Test and the Continuous Dopaminergic Stimulation in Complicated Parkinson's Disease. <i>European Neurology</i> , 1992, 32, 65-69.	0.6	8
234	Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. <i>Parkinsonism and Related Disorders</i> , 1998, 4, 183-188.	1.1	8



#	ARTICLE	IF	CITATIONS
235	Extensive validation study of the Parkinson's Disease Composite Scale. <i>European Journal of Neurology</i> , 2019, 26, 1281-1288.	1.7	8
236	Abnormalities of Cortical Sources of Resting State Delta Electroencephalographic Rhythms Are Related to Epileptiform Activity in Patients With Amnesic Mild Cognitive Impairment Not Due to Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 514136.	1.1	8
237	Resting State Alpha Electroencephalographic Rhythms Are Differently Related to Aging in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1085-1114.	1.2	8
238	Resting State Alpha Electroencephalographic Rhythms Are Affected by Sex in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment: A Retrospective and Exploratory Study. <i>Cerebral Cortex</i> , 2022, 32, 2197-2215.	1.6	8
239	Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration. <i>Journal of Neurology</i> , 1988, 27, 27-33.		8
240	Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021, 93, 27-30.	1.1	8
241	Sleep disorders in Parkinson's disease. <i>Advances in Neurology</i> , 2001, 86, 289-93.	0.8	8
242	One year treatment with lisuride delivery pump in Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1989, 13, 173-183.	2.5	7
243	Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. <i>Journal of Neural Transmission</i> , 2015, 122, 799-808.	1.4	7
244	Does fatigue in Parkinson's disease correlate with autonomic nervous system dysfunction?. <i>Neurological Sciences</i> , 2018, 39, 2169-2174.	0.9	7
245	Football Players Do Not Show "Neural Efficiency" in Cortical Activity Related to Visuospatial Information Processing During Football Scenes: An EEG Mapping Study. <i>Frontiers in Psychology</i> , 2019, 10, 890.	1.1	7
246	A novel summary kinematic index for postural characterization in subjects with Parkinson's disease. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2020, 56, 142-147.	1.1	7
247	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. <i>Frontiers in Neurology</i> , 2021, 12, 754016.	1.1	7
248	Instrumental diagnosis of multiple system atrophy. <i>Advances in Neurology</i> , 1996, 69, 421-4.	0.8	7
249	Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus. <i>Npj Parkinson's Disease</i> , 2022, 8, 17.	2.5	7
250	Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease. <i>International Journal of Psychophysiology</i> , 2022, 177, 179-201.	0.5	7
251	Implantable venous access system for apomorphine infusion in complicated Parkinson's disease. <i>Movement Disorders</i> , 1999, 14, 358-358.	2.2	6
252	Applications of the European Parkinson's Disease Association sponsored Parkinson's Disease Composite Scale (PDCS). <i>Npj Parkinson's Disease</i> , 2019, 5, 26.	2.5	6

#	ARTICLE	IF	CITATIONS
253	The coefficient of friction in Parkinson's disease gait. <i>Functional Neurology</i> , 2017, 32, 17.	1.3	6
254	Urodynamic study in the differential diagnosis between multiple system atrophy and Parkinson's disease. <i>Advances in Neurology</i> , 1993, 60, 434-7.	0.8	6
255	Unusual Cardiovascular Response to Intravenous Lisuride Bolus. <i>Chest</i> , 1987, 91, 792-793.	0.4	5
256	Initiating levodopa therapy for Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 430-430.	2.2	5
257	Peripheral neurostimulation breaks the shuffling steps patterns in Parkinsonian gait: a double blind randomized longitudinal study with automated mechanical peripheral stimulation. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2019, 54, 860-865.	1.1	5
258	Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial. <i>Neurology and Therapy</i> , 2022, 11, 1409-1425.	1.4	5
259	QT interval and QT dispersion in multiple system atrophy (Shy-Drager syndrome). <i>Clinical Autonomic Research</i> , 1996, 6, 67-70.	1.4	4
260	The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study. <i>Future Microbiology</i> , 2020, 15, 1393-1404.	1.0	4
261	Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1155-1172.	1.0	4
262	Functional gait disorders: Demographic and clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 32-36.	1.1	4
263	Classification of Patients with Alzheimer's Disease and Dementia with Lewy Bodies using Resting EEG Selected Features at Sensor and Source Levels: A Proof-of-Concept Study. <i>Current Alzheimer Research</i> , 2021, 18, 956-969.	0.7	4
264	Neuroprotection in Parkinson's disease: clinical trials. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2007, 84, 17-29.	1.0	3
265	Use of the gait profile score for the quantification of the effects of robot-assisted gait training in patients with Parkinson's disease. , 2016, , .		3
266	Effectiveness of an herbaceous derivatives, PHGG, plus sodium hyaluronate in the treatment of chronic constipation in patients with Parkinson's disease: a pilot study. <i>Neurological Sciences</i> , 2022, 43, 1055-1059.	0.9	3
267	Morbo di Parkinson. <i>The Neuroradiology Journal</i> , 1993, 6, 99-103.	0.1	2
268	An acute and long-term study with a dispersible formulation of levodopa/benserazide (Madopar®) in Parkinson's disease. <i>European Journal of Neurology</i> , 1997, 4, 485-490.	1.7	2
269	Managing the critical problems of advanced Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2002, 2, 835-847.	1.4	2
270	Combination of two different dopamine agonists in the management of Parkinson's disease. <i>Neurological Sciences</i> , 2002, 23, s115-s116.	0.9	2



#	ARTICLE	IF	CITATIONS
271	I.P2 Prevalence of non motor symptoms in Parkinson's Disease: An international survey using NMSQuest in 525 patients. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 21.	1.1	2
272	Neuroprotection in Parkinson's disease: a difficult challenge. <i>Lancet Neurology</i> , The, 2015, 14, 780-781.	4.9	2
273	Mining clinical and laboratory data of neurodegenerative diseases by Machine Learning: transcriptomic biomarkers. , 2018, , .		2
274	Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar). <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2605-2613.	1.1	2
275	Ongoing Electroencephalographic Rhythms Related to Exploratory Movements in Transgenic TASTPM Mice. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 291-308.	1.2	2
276	Are there clinically significant differences between dopamine agonists. <i>Advances in Neurology</i> , 2003, 91, 259-66.	0.8	2
277	Alzheimer's Disease with Epileptiform EEG Activity: Abnormal Cortical Sources of Resting State Delta Rhythms in Patients with Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-29.	1.2	2
278	Transient left bundle branch block following intravenous lisuride bolus. <i>Fundamental and Clinical Pharmacology</i> , 1993, 7, 115-117.	1.0	1
279	Chronic BACE-1 Inhibitor Administration in TASTPM Mice (APP KM670/671NL and PSEN1 M146V Mutation): An EEG Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9072.	1.8	1
280	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson's and Lewy body diseases. <i>Alzheimer's and Dementia</i> , 2020, 16, e045886.	0.4	1
281	A systematic review on the clinical experience with melevodopa/carbidopa fixed combination in patients with Parkinson disease. <i>Minerva Medica</i> , 2020, 110, 575-585.	0.3	1
282	The epsilon (early Parkinson with L-dopa/DDCi and opicapone) study in early Parkinson's disease: Design and rationale of a phase III, double-blind, randomized, placebo-controlled study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119422.	0.3	1
283	BouNDless: An active-controlled, randomised, double-blind, double-dummy trial of continuous subcutaneous infusion of levodopa/carbidopa with ND0612 in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 79, e53.	1.1	1
284	Parietal intrahemispheric source connectivity of resting-state electroencephalographic alpha rhythms is abnormal in Naïve HIV patients. <i>Brain Research Bulletin</i> , 2022, 181, 129-143.	1.4	1
285	Cardiovascular Effects of Lisuride Continuous Intravenous Infusion in Fluctuating Parkinson's Disease. <i>Clinical Neuropharmacology</i> , 1990, 13, 360.	0.2	0
286	Urodynamic and Neurophysiological Evaluation in Parkinson's Disease and Multiple System Atrophy. <i>Journal of Urology</i> , 1999, 161, 2033-2033.	0.2	0
287	Abnormalities of Resting State Functional Cortical Connectivity in Patients with Dementia Due to Alzheimer's and Lewy Body Diseases: An EEG Study. <i>Alzheimer's and Dementia</i> , 2018, 14, P244.	0.4	0
288	Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: Post-hoc analysis from double-blind combined BIPARK-I and II data. <i>Journal of the Neurological Sciences</i> , 2019, 405, 200-201.	0.3	0

#	ARTICLE	IF	CITATIONS
289	Efficacy of opicapone in Parkinson's disease patients with "early" motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience. <i>Journal of the Neurological Sciences</i> , 2019, 405, 191-192.	0.3	0
290	Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results from patients who ended 1-year BIPARK-I extension on opicapone 50 mg. <i>Journal of the Neurological Sciences</i> , 2019, 405, 237.	0.3	0
291	Efficacy of opicapone in Parkinson's disease patients according to baseline pramipexole use: A post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 192-193.	0.3	0
292	Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline disease severity: Post-hoc analysis from double-blind combined BIPARK-I and II data. <i>Journal of the Neurological Sciences</i> , 2019, 405, 201-202.	0.3	0
293	Incidence of treatment-emergent adverse events in Parkinson's disease patients according to race: Post-hoc analysis from double-blind combined BIPARK-I and II data. <i>Journal of the Neurological Sciences</i> , 2019, 405, 202-203.	0.3	0
294	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinson's and Lewy body diseases. <i>Alzheimer's and Dementia</i> , 2020, 16, e045811.	0.4	0
295	Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage. <i>Alzheimer's and Dementia</i> , 2020, 16, e045832.	0.4	0
296	An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 965-972.	0.9	0
297	Study design to assess the effect of opicapone on levodopa pharmacokinetics in different levodopa-optimized treatment regimens in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119438.	0.3	0
298	Long-term efficacy of opicapone in the reduction of on-time with troublesome dyskinesia in Parkinson's disease patients with motor fluctuations and reporting troublesome dyskinesia. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119442.	0.3	0
299	Efficacy of opicapone at different levodopa regimens up to a threshold of 600 mg/day levodopa in Parkinson's disease patients with motor fluctuations. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119445.	0.3	0
300	Adoption (early levodopa with opicapone in Parkinson's patients with motor fluctuations) study in Parkinson's disease: Design and rationale of a randomized prospective, open-label exploratory trial. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119423.	0.3	0
301	Problems of Long-Term Levodopa Treatment. <i>Advances in Behavioral Biology</i> , 2002, , 397-402.	0.2	0
302	Gastrointestinal, Urological, and Sleep Problems in Parkinson's Disease. , 2005, , 251-275.		0
303	Levodopa and lisuride intravenous infusions in fluctuating Parkinsonian patients: clinical differences. , 1990, , 151-160.		0
304	Effect of baseline dyskinesia on safety and efficacy of istradefylline, an A2A receptor antagonist, in Parkinson's disease: 8-study pooled analysis. <i>Parkinsonism and Related Disorders</i> , 2020, 79, e55-e56.	1.1	0
305	Resting-state alpha electroencephalographic rhythms are differently related to gender in cognitively unimpaired seniors and in patients with amnesic mild cognitive impairment due to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
306	Reduction in posterior cortical alpha rhythms during eye opening is more abnormal in patients with dementia due to Lewy bodies than Alzheimer's disease: An EEG study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
307	Relationship between cortical neural synchronization at alpha resting-state electroencephalographic rhythms and education attainment in normal elderly subjects and patients with amnesic mild cognitive impairment due to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
308	Patients with amnesic mild cognitive impairment due to Alzheimer's disease and with epileptiform-like signatures showed abnormal cortical sources of resting state delta EEG rhythms: An EEG study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
309	Education and brain amyloid load act on temporal lobe function in individual with subjective memory complaint: An EEG-fMRI study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
310	Digital Scientific Platform for Independent Content in Neurology: Rigorous Quality Guideline Development and Implementation. <i>Interactive Journal of Medical Research</i> , 2022, 11, e35698.	0.6	0